With more than half of patients with MDD failing to achieve response or remission,1 it is time to look at new potential pathways and processes in depression. Explore this website to learn more about these pathways and the unmet needs in patient management of MDD.
Treating patients with MDD presents a challenge—disease progression and response can vary greatly.2 It may be time to look beyond current pathways to advance our understanding of this disorder.REVIEW CHALLENGES
Advance your understanding of approaches and pathways in MDD with a selection of videos and conference presentations from various experts in the treatment of depression.VIEW PRESENTATIONS
References: 1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
Am J Psychiatry. 2006;163(11):1905-1917. 2. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4(5):937‐948. 3. Dale E, Bang-Andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol. 2015;95(2):81-97.
4. Kennedy SE, Koeppe RA, Young EA, Zubieta J-K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63(11):1199-1208.
©2018 Alkermes, Inc. All rights reserved.